ATE304849T1 - Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung - Google Patents

Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung

Info

Publication number
ATE304849T1
ATE304849T1 AT01958941T AT01958941T ATE304849T1 AT E304849 T1 ATE304849 T1 AT E304849T1 AT 01958941 T AT01958941 T AT 01958941T AT 01958941 T AT01958941 T AT 01958941T AT E304849 T1 ATE304849 T1 AT E304849T1
Authority
AT
Austria
Prior art keywords
cyanomethyl
treatment
diseases related
imidazolium compounds
protein aging
Prior art date
Application number
AT01958941T
Other languages
English (en)
Inventor
Dilip Wagle
Sheng Ding Fang
Original Assignee
Alteon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteon Inc filed Critical Alteon Inc
Application granted granted Critical
Publication of ATE304849T1 publication Critical patent/ATE304849T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01958941T 2000-07-13 2001-07-13 Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung ATE304849T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21827300P 2000-07-13 2000-07-13
US25943100P 2000-12-29 2000-12-29
US25924201P 2001-01-02 2001-01-02
US29643501P 2001-06-06 2001-06-06
PCT/US2001/022200 WO2002008210A1 (en) 2000-07-13 2001-07-13 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging

Publications (1)

Publication Number Publication Date
ATE304849T1 true ATE304849T1 (de) 2005-10-15

Family

ID=27499106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01958941T ATE304849T1 (de) 2000-07-13 2001-07-13 Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung

Country Status (10)

Country Link
US (8) US20020068729A1 (de)
EP (3) EP2085086A3 (de)
JP (2) JP2004504389A (de)
AT (1) ATE304849T1 (de)
AU (4) AU8054601A (de)
CA (2) CA2415362A1 (de)
DE (1) DE60113548T2 (de)
ES (1) ES2251500T3 (de)
MX (2) MXPA03000386A (de)
WO (2) WO2002007725A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
MXPA02008276A (es) * 2000-02-23 2004-04-05 Alteon Inc Compuestos de tiazolio y tratamientos de trastornos asociados con el envejecimiento proteinico.
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2251500T3 (es) * 2000-07-13 2006-05-01 Alteon, Inc. Tiazolios e imidazolios sustituidos por cianometilo y tratamientos de desordenes asociados al envejecimiento proteinico.
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1353676A4 (de) 2000-12-29 2006-05-31 Alteon Inc Methode zur behandlung von fibrosen oder anderen indikationen
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
EP1401437A1 (de) * 2001-06-15 2004-03-31 3M Innovative Properties Company Immunantwort-modifizierenden verbindungen zur behandlung von periodontalen erkrankungen
AU2003239868A1 (en) 2002-05-23 2003-12-12 Tony Maniscalco Sunscreen compositions and methods of use thereof
US7144570B2 (en) * 2002-05-23 2006-12-05 Alteon, Inc. Sunscreen compositions and methods of use thereof
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
BRPI0416936A (pt) 2003-11-25 2007-01-16 3M Innovative Properties Co sistemas de anel de imidazo substituìdos e métodos
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1750862B1 (de) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
JP2008513479A (ja) * 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN101007789B (zh) * 2006-01-27 2014-08-20 北京摩力克科技有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
WO2009023207A1 (en) * 2007-08-13 2009-02-19 Synvista Therapeutics, Inc. Thiazolium compounds for treating gastrointestinal complications
WO2009051804A1 (en) * 2007-10-18 2009-04-23 Synvista Therapeutics, Inc. Thiazolium compounds for treating or preventing diseases associated with insulin resistance
WO2009096905A1 (en) * 2008-01-30 2009-08-06 Agency For Science, Technology And Research Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
WO2009123569A1 (en) * 2008-03-31 2009-10-08 Agency For Science, Technology And Research Method for treating neurological disorders with imidazolium and imidazolinium compounds
CN104277011A (zh) * 2013-07-09 2015-01-14 中国人民解放军军事医学科学院毒物药物研究所 噻唑内盐类化合物及其治疗蛋白老化相关疾病的用途
WO2015051258A1 (en) 2013-10-03 2015-04-09 David Spiegel Crosslink breakers for preservation of biological substances
US10716813B2 (en) * 2016-05-06 2020-07-21 Unicyte Ev Ag Pharmaceutical carriers containing miRNAs for use in the treatment of fibrotic diseases caused by hyperglycemia
CN106505185B (zh) * 2016-11-16 2019-11-15 南京师范大学 一种锑/氮掺杂碳复合物及其制备方法和应用
WO2021125905A1 (ko) * 2019-12-20 2021-06-24 가천대학교 산학협력단 신규한 티아졸 유도체 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210096D0 (en) * 1992-05-11 1992-06-24 Fujisawa Pharmaceutical Co 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives and their preparation
CA2210684C (en) * 1995-01-18 2008-01-15 Alteon Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5850840A (en) * 1995-11-15 1998-12-22 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
JPH107709A (ja) * 1996-06-24 1998-01-13 Toyo Ink Mfg Co Ltd 感エネルギー線活性剤組成物、それを用いた感応性組成物ならびに画像形成用組成物
US6391899B1 (en) * 1998-07-17 2002-05-21 North Shore—Long Island Jewish Research Institute Compounds and compositions for treating tissue ischemia
WO2000012102A1 (en) * 1998-08-31 2000-03-09 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
EP1267855A2 (de) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Company Vasopeptidase inhibitoren zur behandlung des isolierten, systolischen bluthochdrucks
US20030176426A1 (en) * 2000-07-13 2003-09-18 Alteon, Inc. Method for treating fibrotic diseases or other indications with imidazolium agents
ES2251500T3 (es) * 2000-07-13 2006-05-01 Alteon, Inc. Tiazolios e imidazolios sustituidos por cianometilo y tratamientos de desordenes asociados al envejecimiento proteinico.
MXPA03005922A (es) * 2000-12-29 2004-05-04 Alteon Inc Metodo para tratar glaucoma ib.
US6853703B2 (en) * 2001-07-20 2005-02-08 Siemens Medical Solutions Usa, Inc. Automated delivery of treatment fields

Also Published As

Publication number Publication date
AU2001280551B9 (en) 2006-01-12
EP1303501A1 (de) 2003-04-23
DE60113548D1 (de) 2006-02-02
US20040235837A1 (en) 2004-11-25
AU8054601A (en) 2002-02-05
US20070099892A1 (en) 2007-05-03
US20020177586A1 (en) 2002-11-28
WO2002007725A1 (en) 2002-01-31
CA2415054A1 (en) 2002-01-31
EP1305024A1 (de) 2003-05-02
EP1305024A4 (de) 2006-03-22
EP1303501B1 (de) 2005-09-21
US7166625B2 (en) 2007-01-23
US6610716B2 (en) 2003-08-26
US20090124674A1 (en) 2009-05-14
JP2004504389A (ja) 2004-02-12
AU8055101A (en) 2002-02-05
ES2251500T3 (es) 2006-05-01
MXPA03000386A (es) 2004-02-26
US20090124673A1 (en) 2009-05-14
US20020068729A1 (en) 2002-06-06
EP2085086A2 (de) 2009-08-05
US20020103182A1 (en) 2002-08-01
AU2001280546B2 (en) 2005-10-20
AU2001280551B2 (en) 2005-11-17
DE60113548T2 (de) 2006-06-22
US20050032865A1 (en) 2005-02-10
MXPA03000388A (es) 2003-09-25
JP2004504348A (ja) 2004-02-12
EP1303501A4 (de) 2004-03-03
CA2415362A1 (en) 2002-01-31
WO2002008210A1 (en) 2002-01-31
EP2085086A3 (de) 2009-11-25

Similar Documents

Publication Publication Date Title
ATE304849T1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
NL300808I2 (nl) susoctocog alfa
ES2060951T5 (es) Azaindenos.
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
NO20033617L (no) Fremgangsmate for behandling av diabetes mellitus
ATE495736T1 (de) Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel
ATE317894T1 (de) Desinfizierendes waschen empfindlicher textilien mit persäuren
ATE254461T1 (de) Behandlung von augenschmerzen
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE402699T1 (de) Verwendung von substituierten pyrazolen zur behandlung von allergien
CY1111900T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69924979D1 (de) Behandlung von chronischen schmerzen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
ATE486594T1 (de) Methode zur behandlung von herzinsuffizienz
ATE369849T1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
SE0100873D0 (sv) Method of treatment
DE60312840D1 (de) Verwendung von hydroxypyridon derivaten zur wundheilung
ATE382367T1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties